Eli Lilly amylin-Zepbound combo achieves record weight loss in diabetes study

Statements (5)

1. ▲ Bullish

   Eli Lilly reported its best-ever weight loss data

   endpoints.newsOct 3, 2026 10:00 UTCHigh importance
2. ▲ Bullish

   Eli Lilly said its combo obesity regimen boosts weight loss in a mid-stage trial

   cnbc.comSep 30, 2026 14:32 UTCHigh importance
3. ▲ Bullish

   Lilly's new experimental amylin drug combined with Zepbound helped people lose up to 23% of their weight

   marketwatch.comSep 30, 2026 14:32 UTC
4. ▲ Bullish

   Lilly's amylin-Zepbound combination posted best-ever weight loss of up to 23.3% in patients with obesity and diabetes

   endpoints.newsSep 30, 2026 14:15 UTCHigh importance
5. ▲ Bullish

   Lilly's drug combination achieved record weight loss in a diabetes study

   bloomberg.comSep 30, 2026 14:15 UTC